Logo

AKTX

Akari Therapeutics, Plc

AKTX

Akari Therapeutics, Plc • NASDAQ
$0.49 ▲ 9.06% (+0.04)
Market Cap $8691
52w High $1.73
52w Low $0.42
Dividend Yield 0%
P/E -0.19
Volume 59.75K
Outstanding Shares 17.87K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.211M ▼ $-6.362M ▼ 0% $-19.48K ▼ $-7.323M ▼
Q2-2025 $0 $3.119M ▼ $-1.895M ▲ 0% $-120.4 ▲ $-1.845M ▲
Q1-2025 $0 $3.525M ▼ $-3.705M ▲ 0% $-280 ▼ $-3.65M ▼
Q4-2024 $0 $4.294M ▲ $-3.772M ▼ 0% $-40 ▲ $-3.647M ▼
Q3-2024 $0 $2.927M $-2.895M 0% $-240 $-2.826M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.484M ▼ $45.376M ▼ $22.689M ▼ $22.687M ▼
Q2-2025 $2.711M ▲ $50.911M ▼ $25.306M ▼ $25.605M ▲
Q1-2025 $2.582M ▼ $50.959M ▲ $29.213M ▲ $21.746M ▼
Q4-2024 $2.599M ▲ $50.562M ▲ $28.333M ▲ $22.229M ▲
Q3-2024 $2.246M $2.734M $9.428M $-6.694M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.362M ▼ $-2.102M ▲ $0 $1.876M ▼ $-227K ▼ $-2.102M ▲
Q2-2025 $-1.895M ▲ $-3.256M ▼ $0 $3.381M ▲ $129K ▲ $-3.256M ▼
Q1-2025 $-3.705M ▲ $-2.15M ▼ $0 ▼ $2.133M ▼ $-17K ▼ $-2.15M ▼
Q4-2024 $-3.772M ▼ $-2.124M ▼ $382K ▲ $2.154M ▲ $413K ▲ $-2.124M ▼
Q3-2024 $-2.895M $-1.49M $0 $-443K $-1.931M $-1.49M

Five-Year Company Overview

Income Statement

Income Statement Akari is still a pure research-stage biotech with no product revenue at all. The income statement is dominated by research and operating costs, which naturally produce recurring losses each year. Those losses appear relatively steady rather than exploding, but they are not shrinking meaningfully either. The very large swings in reported earnings per share are mostly a side effect of repeated reverse stock splits, not a change in the underlying business. Overall, the picture is of a classic early‑stage biotech: costs to fund science, no commercial income yet, and ongoing accounting losses that are likely to continue until a drug is approved or partnered.

Balance Sheet

Balance Sheet The balance sheet is very light: only a small pool of assets and, historically, mostly cash. There is no reported financial debt, which reduces balance‑sheet risk, but equity is also quite thin. That means there is only a modest cushion to absorb continued losses, and the company’s capacity to self‑fund long development timelines is limited. In effect, Akari has a clean but fragile balance sheet: simple structure, no leverage, but also not a lot of resources relative to the long and expensive path of drug development.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing spending on research, staff, and overhead without any offsetting revenue. Free cash flow is also negative and tracks operating cash burn closely, since capital spending is negligible. This is typical for a virtual or very lean biotech platform. The key implication is that the company’s progress depends on continued access to external capital or partnership funding. Without new funding sources, the current cash burn pattern would limit how long Akari can run its full R&D program at the present pace.

Competitive Edge

Competitive Edge Akari operates in very competitive areas—oncology antibody‑drug conjugates and treatments for geographic atrophy—where it faces large, well‑funded pharmaceutical companies. Its differentiator is not scale but scientific angle: a novel ADC payload mechanism and deep complement biology know‑how. If the PH1 payload and Trop2‑targeted AKTX‑101 perform as hoped, they could stand out in resistant cancers and in combination with immunotherapies. Similarly, PAS‑nomacopan’s dual‑pathway approach and potentially less frequent dosing could differentiate it from current eye drugs. However, all of this is still early and unproven in large human studies, so the competitive position today is more about potential than demonstrated market strength.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Akari’s story. The company has pivoted from autoimmune disease toward a next‑generation oncology platform based on a novel spliceosome‑inhibiting payload (PH1) used in ADCs. This payload is designed to both kill tumor cells directly and trigger stronger immune responses, which may help in tumors that resist standard treatments and could pair well with checkpoint inhibitors. The lead candidate, AKTX‑101, goes after a widely expressed tumor marker, suggesting broad cancer applications if it works. Alongside this, PAS‑nomacopan for geographic atrophy builds on Akari’s legacy complement research, aiming to address both disease progression and complications, with the promise of less frequent eye injections. The company is building patents around these technologies, which could protect its space if the science translates in the clinic—but nearly all key value drivers remain in preclinical or very early development, so scientific and regulatory uncertainty is high.

Summary

Akari Therapeutics today is a small, pre‑revenue biotech with a balance sheet and cash flows that reflect ongoing R&D spending and limited financial resources. It has no commercial products, persistent but manageable losses, and no debt, but it does face the usual funding risk of a micro‑cap drug developer. The investment story rests almost entirely on its innovation: a differentiated ADC platform for cancer and a legacy ophthalmology asset with a novel dual mechanism. Both programs address large, competitive markets and offer scientific angles that could stand out, but they are still early and unproven in human trials. Overall, Akari is best viewed as a high‑uncertainty, science‑driven platform whose future will depend on clinical results, regulatory progress, and its ability to secure partnerships or additional capital to keep the R&D engine running.

NEWS

November 25, 2025 · 9:00 AM UTC

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Read more

November 18, 2025 · 8:35 AM UTC

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Read more

November 10, 2025 · 8:30 AM UTC

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Read more

November 4, 2025 · 9:25 AM UTC

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Read more

October 30, 2025 · 8:35 AM UTC

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Read more